Filtered By:
Condition: Atrial Fibrillation
Procedure: Percutaneous Coronary Intervention

This page shows you your search results in order of relevance. This is page number 6.

Order by Relevance | Date

Total 371 results found since Jan 2013.

Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies
This review aims to provide insights into contemporary therapeutic options for the treatment of patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) and compares current international guidelines. AF is a common cardiac arrhythmia and a major risk factor for stroke. The risk of stroke can be reduced with the use of oral anticoagulant (OAC) therapy. However, for patients with AF, PCI necessitates the use of combined antithrombotic therapies (OAC and antiplatelet therapies) to reduce thrombotic coronary complications.
Source: Atherosclerosis - August 29, 2019 Category: Cardiology Authors: Kevin R. Bainey, Jo ão Morais, Uwe Zeymer, Robert C. Welsh Tags: Review article Source Type: research

A drug safety evaluation of apixaban for the treatment of atrial fibrillation, acute coronary syndrome and percutaneous coronary intervention.
Authors: Gumprecht J, Domek M, Lip GY Abstract Introduction: The non-vitamin K antagonist oral anticoagulants (NOACs) are changing the landscape for stroke prevention in atrial fibrillation (AF) and prevention or treatment of venous thromboembolism (VTE). In patients with AF and concomitant acute coronary syndrome (ACS), the treatment regimen of combined NOACs and P2Y12 inhibitors is gaining popularity. Areas covered: The authors conducted a review of studies published in the last 10 years regarding safety evaluation and effectiveness of apixaban for the treatment of AF and ACS, both alone and in combination with d...
Source: Expert Opinion on Drug Safety - October 4, 2019 Category: Drugs & Pharmacology Tags: Expert Opin Drug Saf Source Type: research

Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI
AbstractTriple anti-thrombotic therapy combining oral anticoagulation and dual anti-platelet therapy following percutaneous coronary intervention in patients with atrial fibrillation was considered as standard and recommended by guidelines. While bleeding risk is considerable with that approach, data for efficacy are scare. Several trials assessed the possibility of reducing anti-thrombotic treatment by mainly shortening the exposure to acetylsalicylic acid. Dropping one of the anti-platelet components might increase the risk of stent thrombosis, myocardial infarction or stroke. Despite that fear, the recent trials ’ pri...
Source: Clinical Research in Cardiology - July 20, 2020 Category: Cardiology Source Type: research

Prognostic value of CHADS2 and CHA2DS2-VASc scores for post-discharge outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention
This study aimed to investigate the association of CHADS2 and CHA2DS2-VASc scores with CV outcomes in such patients. We included a total of 915 ACS patients undergoing PCI in this study. CHADS2 and CHA2DS2-VASc scores were calculated from data collected before discharge. The primary endpoint was defined as a composite of major adverse CV events (MACE) including overall death, nonfatal stroke, nonfatal myocardial infarction (MI) and unplanned repeat revascularization. We assessed MACE's relationship to CHADS2 and CHA2DS2-VASc scores using Cox proportional-hazard regression analyses. Mean follow-up duration was 918 days. M...
Source: Medicine - July 24, 2020 Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research

Antithrombotic Therapy and Outcomes of Patients With New-Onset Transient Atrial Fibrillation After ST-Segment Elevation Myocardial Infarction
Conclusions: There is not a widely accepted treatment algorithm in patients with STEMI who complicated with new-onset AF in clinical guidelines. The current study indicated that transient form of new-onset AF might not require long-term VKA. Besides, addition of VKA to DAPT therapy may increase the rates of major and minor bleeding.
Source: American Journal of Therapeutics - December 31, 2020 Category: Drugs & Pharmacology Tags: Original Investigations Source Type: research

Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation
CONCLUSION: After coronary stent implantation, dual therapy with a NOAC and a P2Y12 inhibitor is recommended, subsequent to triple therapy given only during the peri-interventional period.PMID:33637173 | DOI:10.3238/arztebl.m2021.0150
Source: Deutsches Arzteblatt International - February 27, 2021 Category: General Medicine Authors: Conrad Genz Ruediger C Braun-Dullaeus Source Type: research

Long-term cardiovascular outcomes and temporal trends in patients diagnosed with ANCA-associated vasculitis: a Danish nationwide registry study
ConclusionsPatients with AAV are at increased risk of heart failure, atrial-/ventricular arrhythmias, venous thrombotic events, ischaemic stroke and myocardial infarction. Furthermore, patients with AAV were more frequently examined with coronary procedures and underwent more coronary revascularizations. No temporal changes in ischaemic cardiovascular outcomes were observed, albeit the cardiovascular mortality has decreased over time.
Source: Rheumatology - July 5, 2022 Category: Rheumatology Source Type: research

Comparison of early and late clinical outcomes in patients >= 80 versus
Conclusion: Age is an independent predictor of mortality after p-PCI for STEMI. Although it seems to improve early outcomes, the efficacy of p-PCI at long-term follow-up is limited in elderly patients. PMID: 23760119 [PubMed - in process]
Source: Turk Kardiyoloji Dernegi arsivi - June 16, 2013 Category: Cardiology Authors: Oduncu V, Erkol A, Tanalp AC, Kırma C, Bulut M, Bitigen A, Pala S, Tigen K, Esen AM Tags: Turk Kardiyol Dern Ars Source Type: research

Thrombocytopenia in Patients With Atrial Fibrillation on Oral Anticoagulation Undergoing Percutaneous Coronary Intervention
In conclusion, mild to moderate baseline thrombocytopenia does not seem to have a clinically significant effect on bleeding or thrombotic or thromboembolic complications after PCI in these frail patients receiving multiple antithrombotic drugs.
Source: The American Journal of Cardiology - May 13, 2013 Category: Cardiology Authors: Tuomas Kiviniemi, Pasi Karjalainen, Andrea Rubboli, Axel Schlitt, Petri Tuomainen, Matti Niemelä, Mika Laine, Fausto Biancari, Gregory Y.H. Lip, K.E. Juhani Airaksinen Tags: Coronary Artery Disease Source Type: research

188 * clinical and angiographic comparison of bilateral internal thoracic artery configurations: y composite grafting is superior to in situ
Conclusions: Composite grafting showed better clinical outcome in this single RITA anastomosis setting and could be the best option.
Source: Interactive CardioVascular and Thoracic Surgery - September 18, 2013 Category: Cardiovascular & Thoracic Surgery Authors: de Beco, G., El Khoury, G., Noirhomme, P., de Kerchove, L., Astarci, P., Etienne, P., Glineur, D. Tags: Arterial revascularization Source Type: research